| abstract |
The present invention relates to a group of 2 - {[1-substituted-1 H -pyrazolo [3,4-d] pyrimidin-4-yl] (thio, oxy or amino) -N- (heteroaryl) alkanides which are useful in the treatment or prevention of a disease or medical condition mediated by glucokinase (GLK or GK). It is known that activators of (GK (GKA) activate GK in β-pancreatic cells, which leads to a reduction of the glucose threshold for insulin secretion. Additionally, GKA activates hepatic GK. Thus stimulating uptake of hepatic glucose and suppressing hepatic glucose output The net pharmacological effect of GKA is to reduce blood glucose levels, therefore, such compounds may be useful in the treatment of type 2 diabetes and obesity. The invention also relates to pharmaceutical compositions comprising said compounds and methods of treating GLK-mediated diseases using said compounds. |